Avior Wealth Management LLC Increases Position in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Avior Wealth Management LLC lifted its position in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 1,118.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,569 shares of the medical instruments supplier’s stock after acquiring an additional 13,373 shares during the period. Avior Wealth Management LLC’s holdings in Harvard Bioscience were worth $39,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. boosted its holdings in shares of Harvard Bioscience by 193.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock valued at $649,000 after acquiring an additional 150,218 shares during the last quarter. Bank of New York Mellon Corp grew its position in Harvard Bioscience by 13.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 274,635 shares of the medical instruments supplier’s stock worth $783,000 after purchasing an additional 31,505 shares during the period. Vanguard Group Inc. raised its stake in shares of Harvard Bioscience by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock valued at $9,125,000 after buying an additional 49,576 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Harvard Bioscience by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 745,278 shares of the medical instruments supplier’s stock valued at $2,124,000 after buying an additional 42,800 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Harvard Bioscience by 24.9% in the 2nd quarter. Rhumbline Advisers now owns 47,753 shares of the medical instruments supplier’s stock valued at $136,000 after buying an additional 9,512 shares during the period. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Stock Down 1.3 %

Harvard Bioscience stock opened at $2.24 on Tuesday. Harvard Bioscience, Inc. has a 52 week low of $1.99 and a 52 week high of $5.56. The firm has a market cap of $97.71 million, a price-to-earnings ratio of -6.79 and a beta of 1.31. The business’s 50-day moving average price is $2.45 and its 200 day moving average price is $2.82. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.